Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Saved in:
Bibliographic Details
Title: Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
Authors: Pradeep C-; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.; Department of Systems Biology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA., Zeisel A; Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel., Köstler WJ; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.; Clinical Division of Oncology, Department of Medicine 1 and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Lauriola M; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Jacob-Hirsch J; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Haibe-Kains B; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.; Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium., Amariglio N; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Ben-Chetrit N; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Emde A; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Solomonov I; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel., Neufeld G; Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel., Piccart M; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium., Sagi I; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel., Sotiriou C; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium., Rechavi G; Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Domany E; Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel., Desmedt C; Institut Jules Bordet, Translational Research Unit, Brussels, Belgium., Yarden Y; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. yosef.yarden@weizmann.ac.il.
Source: Oncogene [Oncogene] 2024 Apr; Vol. 43 (17), pp. 1317.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5594
DOI:10.1038/s41388-024-02990-w